A pioneering cancer treatment developed by Japanese researchers employs a bacterial consortium named AUN that induces tumor remission independently of the immune system. Comprised of Proteus mirabilis (tumor-resident with no pathogenicity) and Rhodopseudomonas palustris (photosynthetic bacterium enhancing selectivity), this therapy triggers intratumoral thrombosis and necrosis without systemic toxicity. Tested in various syngeneic mouse models, including immunocompromised hosts, AUN has shown high rates of complete tumor responses, offering a promising avenue for cancer therapy in immunosuppressed patients.